Artificial Intelligence for Comprehensive Diagnostics, Examinations in Acute Coronary Syndromes
August 29th 2023Pharmacists can actively engage in the implementation of the Comprehensive Diagnostics and Examinations in Acute Coronary Syndromes pathway within the hospital or health care system.
Read More
Supplemental Biologics License Application Submitted to Expand Approval of Rybrevant for NSCLC
August 29th 2023The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.
Read More
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
August 28th 2023Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.
Read More